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Introduction
The Elapidae family consists of a variety of highly venomous snakes, many of which are found in Australia. The common death adder Acanthophis antarcticus (Serpentes: Elapidae: Acanthophiinae) is usually found in the coastal areas of the states of Queensland, New South Wales (NSW), South Australia and Western Australian [1, 2] and is considered an elapid, despite its viper-like appearance and behaviour. Other Acanthophis spp. have also been identified in Irian Jaya, Papua New Guinea and some eastern Indonesian islands [2] . Symptoms of envenomation from Acanthophis mainly involve neurotoxic symptoms, including ptosis and general flaccid muscle paralysis, with death resulting from respiratory failure [2, 3] . Although some cases of weak haemolytic and anticoagulant activity have been reported [4, 5] , there have been no serious clinical cases of coagulopathies resulting from envenomation, as is common with bites from many other venomous Australian elapid snakes. Envenomation does not produce any clinical signs of myotoxicity, with studies confirming that there is no evidence of skeletal muscle damage [6, 7] . More recent studies have found myotoxicity present in the directly-stimulated chick biventer cervicis nerve-muscle (CBCNM) preparation after incubation with some species of death adder, however A. antarcticus whole venom was devoid of myotoxic activity [8] . Significantly, delayed-onset neurotoxicity is a problem in death adder envenomations, occasionally with late presentation of neurotoxicity as the first feature of envenoming [2, 9, 10] . This has resulted in a recommended hospital admission period of 24 hours for patients in Papua New Guinea and both central and northern Australia, and for children in any region [11] .
The recommended primary treatment for death adder envenomation is CSL monovalent death adder antivenom, which has been raised against A. antarcticus venom [12, 13] , although cross-neutralisation occurs with 'monovalent' taipan and brown snake antivenoms [14] . Death adder antivenom appears to be quite effective in preventing the progression of neurotoxicity from all species of death adder in Australia and Papua New Guinea [2, 3] , showing a rapid reversal of paralysis.
However, some reports have suggested that the neurotoxic effects can be poorly reversed by antivenom or anticholinesterase (neostigmine) if the patient presents late after envenomation [15] . In support, an in vitro study involving A. antarcticus, A. praelongus and A. pyrrhus venoms found that all three venoms produced rapid postsynaptic neurotoxicity but antivenom displayed varying efficacy to reverse toxicity following neuromuscular blockade over a 4 hour period. Indeed, there was only a 22% recovery of contractile responses following complete neuromuscular blockade with A. antarcticus, the venom to which the antivenom is raised [16] .
Acanthophis venoms have long been considered to be composed of predominantly postsynaptic 〈-neurotoxins (for a review see [17] ). However, rapidly developing neurotoxicity from postsynaptic 〈-neurotoxins conceals the action of any underlying snake presynaptic phospholipase A 2 (PLA 2 ; EC 3.1.1.4) neurotoxins (socalled 'β-neurotoxins' or SPANs), that bind to motor nerve terminals to inhibit neurotransmitter release [18] , or myotoxins that may be present in the venom. These toxins typically have slower onsets of activity but bind irreversibly [19, 20] . In the case of patients with delayed-onset or slowly-developing neurotoxicity, SPANS or myotoxins may play a significant role in the speed of recovery following antivenom therapy due to the irreversible nature of their actions, and may go some way to explain the above resistance to antivenom therapy. While a number of monomeric PLA 2 (12-15 kDa) proteins have been isolated from death adder venom (for a review see [17] ), none of these have been characterized pharmacologically. Recently, however, we identified the presence of high molecular mass presynaptic neurotoxic fractions within the venom of A. antarcticus geographic variants and other AustraloPapuan Acanthophis spp. [21] . This study therefore aimed to biochemically and pharmacologically characterise the high molecular mass SPAN complex present within A. antarcticus (NSW variant) venom.
2.
Materials and methods
Venom / toxin preparation and storage
Lyophilized pooled A. antarcticus venom (NSW variant) was provided by the Australian Reptile Park (Gosford, NSW). Death adders were collected from their natural habitats in the Sydney metropolitan region. To minimise the effects of individual variations in venom [22] , venom was collected, pooled and lyophilised (100 mg dry weight) by the supplier. Lyophilised venom and isolated components were stored at -20 o C until required.
Size-exclusion liquid chromatography under non-reducing conditions
Bioassay-guided isolation of the high molecular mass SPAN complex using fastperfusion liquid chromatography of whole venom was performed using a Superdex G-75 column (10 x 300 mm, 13 µm; GE Healthcare, Sydney, NSW, Australia) employing methods described previously [21] . The purified SPAN complex was rerun 6 under the same conditions to ensure purity. The approximate molecular mass of the SPAN complex was then determined following calibration of the Superdex G-75 column with protein standards ranging from 6.5 to 66 kDa, as described previously [21] . The void volume (V o ) of the column was determined by running blue dextran (2,000 kDa), and the elution volume (V e ) was calculated for each molecular mass marker. The molecular mass range of SPAN complexes were then determined from interpolation of a plot of log molecular mass versus retention ratio (V e / V o ) of the standards.
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Reverse-phase high-pressure liquid chromatography (RP-HPLC)
Subunits of the high molecular mass SPAN complex were isolated from the purified size-exclusion fraction using a Chromolith RP-18e column (4.6 x 100 mm;
Merck KGaA, Darmstadt, Germany). Fractions were eluted using an 
Bicinchoninic Acid Protein (BCA) Assay
Following lyophilisation, protein concentrations were determined using the Quantipro™ BCA assay kit (Sigma-Aldrich). Protein contents between 5-200 µg/ml were detected at 560 nm by a Titertek Multiscan Plus MKII plate reader (Flow Laboratories Australasia, North Ryde, NSW). A standard curve was created using bovine serum albumin from which protein concentrations were interpolated.
Mass determination of toxin subunits
Matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass spectrometry
Lyophilised RP-HPLC samples were analysed to determine mass and confirm purity using a Shimadzu AXIMA TOF 2 (Shimadzu Oceania, Rydalmere, NSW, Australia 
Antivenom and suramin reversibility studies
The efficacy of monovalent death adder antivenom (CSL Biotherapies, Melbourne, Australia) or suramin to neutralise the activity of the toxin was assessed by preincubating the organ bath with 5 U/ml of antivenom or 0.3 mM suramin for 10 min prior to addition of venom or toxin. Reversibility studies were also performed by the addition of 5 U/ml monovalent death adder antivenom at 90% inhibition of twitch contractions (t 90 ) or 0.3 mM suramin at 50% inhibition of twitch contractions (t 50 ). An additional study observed the reversibility of toxicity using suramin (0.3 mM) after the toxin was incubated for 30 min and then washed from the bath.
Myotoxicity studies
The myotoxic effects of venom or toxin were examined using direct stimulation of 
Low quantal content studies
The presence of Mg 2+ in the bathing solution facilitates a more pronounced triphasic action of SPANs on twitch contractions [25, 26] . The safety margin for neurotransmitter release was therefore reduced in separate experiments by the addition of 9-17 mM Mg 2+ to the bath [27] . Increasing concentrations of MgCl 2 were titrated to suppress twitch contractions to between 10-30% of initial amplitude. After twitch contractions had stablised for at least 30 min toxin was then added.
Tetanic fade studies
In separate experiments, the ability of the CBCNM preparation to maintain tetanic contractions in response to a short tetanic train of stimuli in the presence of the toxin was investigated. Prior to, and following, addition of toxin to the bath, three 50 Hz, 3 s trains every 10 s were interspersed at 0% (control), 25% (t 25 ), 50% (t 50 ), 75% (t 75 ) and 90% (t 90 ) neuromuscular blockade. These tetanic trains were interspersed between normal 0.05 ms 10 Hz stimulation. The amount of fade in the tetanic response was calculated by comparing the amplitude of the initial (t initial ) and final tension (t final ) during the tetanic train. Tetanic fade was determined from the following equation:
Secretory phospholipase A 2 (sPLA 2 ) activity assay
The sPLA 2 activities of whole venom and isolated toxins were determined using a colorimetric sPLA 2 assay kit (Cayman Chemical Ltd, Ann Arbor, MI) as previously described [21] . sPLA 2 activity was calculated as micromoles of substrate (1,2-dithio analog of diheptanoyl phosphohatidylcholine) hydrolysed per minute per milligram of enzyme (µmol/min/mg), with bee (Apis mellifera) venom as a positive control.
Chemical modification of His 48 using 4-bromophenacyl bromide
The PLA 2 enzymatic activity of the toxin was inhibited by alkylation of the His 48 residue using 4-bromophenacyl bromide (4BPB) as previously described [28] . 330 µg of toxin was prepared in 615 µL of 0.1 M Tris-HCl / 0.7 M EDTA buffer (pH 8.0), to which 10 µL of 4BPB (0.75 mg/ml in ethanol) was subsequently added, and incubated at 25°C for 13 hrs. The modified toxin was collected and lyophilised prior to assaying for sPLA 2 activity and neurotoxicity.
Chemicals and drugs
Unless otherwise stated, all chemicals and drugs were purchased from SigmaAldrich, Castle Hill, NSW, Australia. 
Data analysis
Results
Toxicity of whole venom
Whole A. antarcticus venom (10 µg/ml) produced rapid and complete inhibition of nerve-evoked twitch contractions within 9 ± 1 min (n = 2; Fig. 1A ), whereas with timematched controls there was no significant fatigue of twitch tension over a 240 min period (Fig. 1A) . Whole A. antarcticus venom displayed classical postsynaptic neurotoxic activity, with complete inhibition of responses to exogenous nicotinic agonists (p < 0.001, n = 2; Fig. 1D ).
Venom fractionation under non-denaturing conditions
Prior to separation of whole A. antarcticus venom by size-exclusion FPLC the Sephadex G-75 column was calibrated using a set of molecular weight markers.
Using blue dextran (2,000 kDa), the void volume (V o ) of the Sephadex G-75 column was determined to be 7.6 ml while the elution volume (V e ) of a range of known standards was determined and the molecular mass of unknown complexed was then determined by interpolation of a plot of log molecular mass vs. V e / V o ratio (Fig 2B) .
Under non-reducing conditions, fractionation of whole A. antarcticus venom produced a characteristic pattern of four major peaks ( Fig. 2A) . This was similar to that seen with other geographic variants of A. antarcticus and certain other Australo-Papuan species of Acanthophis [21] . The retention time of the earliest eluting fraction was 12.8-16.0 min, with the peak absorbance at 14.6 min ( Fig. 2A ), corresponding to a molecular mass of ca. 43 kDa (Fig. 2B ).
SPAN complexes typically have molecular weights ranging between 21 kDa (the covalently-linked heterodimer β-bungarotoxin from Bungarus fasciatus; [29] ) and ca.
87 kDa (the heterohexameric textilotoxin; [30] caused a postsynaptic neurotoxic action due to inhibition of responses to the exogenous nicotinic agonists, ACh and CCh (data not shown). Accordingly, the 43 kDa fraction was named P-elapitoxin-Aa1a (P-EPTX-Aa1a) using the rational nomenclature system for naming toxins from spiders and other venomous animals [31] . The activity descriptor prefix 'P' indicates SPANs with a presynaptic action to inhibit neurotransmitter release, 'elapitoxin' is the generic name for toxins from the family Elapidae, 'Aa' are the genus and species descriptor for Acanthophis antarcticus, '1' represents the first family of toxins with this activity ('1' was chosen to represent multimeric SPANs vs. '2' for monomeric SPAN), and 'a' denotes the first paralog (isoform) found.
Neurotoxicity studies with P-EPTX-Aa1a
P-elapitoxin-Aa1a (55-222 nM) produced a concentration-dependent inhibition of nerve-evoked twitch contractions of the CBCNM preparation (Fig. 1B) . The t 90 value for 222 nM P-EPTX-Aa1a for inhibition of twitch contractions was 74 ± 3.5 min (n = 4) that increased to 121 ± 7 min (n = 4) using 55 nM P-EPTX-Aa1a. A slight triphasic timecourse of action characterized by depression-enhancement-blockade of neurotransmission was evident as has been previously reported for a variety of other SPANs in mammalian nerve-muscle preparations [19, 32] . This triphasic action was appreciably enhanced under conditions of low quantal content (high external [Mg 2+ ]), and the t 90 value for inhibition of twitch contractions was also significantly reduced to 41 ± 1 min (p < 0.001, unpaired Student's t-test, n = 3; Fig. 3A ).
Importantly, following complete neuromuscular blockade, P-EPTX-Aa1a failed to inhibit responses to the exogenous cholinergic agonists ACh and CCh or the depolarising agonist KCl (n = 4; Fig. 1D ). Interestingly, the responses to carbachol were enhanced in many fractions, but this has been previously reported in this preparation [33] [34] [35] and may reflect time-dependent sensitization of the tissue to carbachol. Furthermore, P-EPTX-Aa1a failed to induce any significant change in baseline tension (data not shown) or directly-stimulated muscle twitches of the biventer cervicis muscle (n = 4; Fig. 1C ). These actions are consistent with the presence of a SPAN complex that inhibits neurotransmitter release without any additional signs of myotoxicity.
Further support that P-EPTX-Aa1a is a SPAN complex was provided by the ability of the toxin to induce fade in tetanic contractions that contributes to muscle fatigue at more physiological frequencies of nerve stimulation ( Fig. 3B and C) .
Tetanic fade in controls in response to a 3 sec 50 Hz train was minimal in all experiments with a range of 0-6% (1 ± 1%, n = 7). In the presence of the positive control, 1 µM d-tubocurarine, isometric tension rapidly faded to a plateau level. With P-EPTX-Aa1a and taipoxin tetanic fade developed gradually in the initial 500 ms to 1000 ms of the tetanic train to a plateau that was maintained to the end of the train (Fig. 3B) . P-EPTX-Aa1a (55 nM) produced concentration-dependent tetanic fade of 53 ± 11% at t 75 (n = 4; Fig. 3C ). This was less than the positive control, 1 µM dtubocurarine (87 ± 11% at t 75 , n = 4), but greater than the classical heterotrimeric SPAN, taipoxin (32 ± 14% at t 75 , n = 4, 55 nM) previously shown to cause tetanic fade [36] . Interestingly, lower concentrations produced a greater degree of tetanic fade (n = 4; Fig. 3C ).
Neutralisation and reversibility of P-EPTX-Aa1a neurotoxicity
CSL Monovalent death adder antivenom (5 U/ml) was effective in preventing the development of toxicity with P-EPTX-Aa1a (Fig. 1B) . However, reversal of P-EPTXAa1a toxicity by antivenom applied at t 90 was unsuccessful (Fig. 1B) , highlighting the irreversible binding of SPANs. Preincubation with the polysulphonated naphthylurea anti-trypanosomal drug, suramin (0.3 mM), previously shown to inhibit SPAN but not postsynaptic α-neurotoxin toxicity [37, 38] produced a 4.3-fold increase in the time to t 90 of P-EPTX-Aa1a to 315 ± 51 min (p < 0.01, n = 4), but unfortunately failed to completely inhibit neuromuscular blockade (Fig. 4) . The Irreversible nature of toxin binding following only short incubation periods [19, 39] (Fig. 1D) .
Fractionation of the P-EPTX-Aa1a complex
Given that SPAN complexes are commonly derived of between 2 and 6 subunits [30, 40] , P-EPTX-Aa1a subunits were separated under reducing conditions using C18 RP-HPLC to determine the subunit composition. This resulted in three major peaks (Fig. 5A ). The BCA protein assay failed to detect any significant quantities of protein in the early eluting peak at 9.6-10.1 min, and this peak was subsequently excluded from further investigation. The three most abundant peaks, eluting at 16.7, 10.8, and 17.3 min, were named the 〈-, β-, and ©-subunits of P-EPTX-Aa1a, respectively, based on their homology to the molecular masses (see section 3.5) and N-terminal amino acid sequences (see section 3.6) of known multimeric SPAN subunits.
Mass spectrometry of P-EPTX-Aa1a subunits
ESI-Q-TOF mass spectrometry determined the definitive mass of the α-and β-subunits to be 13,809 Da and 13,516 Da, respectively (Figs. 5B and C). MALDI-TOF mass spectrometry determined that the ©-subunit was most likely heterogeneously glycosylated with a nominal mass of 17,373 Da (Fig. 5D ). The sum of the 〈-, ®-and ©-subunit masses resulted in an average mass of 44,698 Da, which is comparable with the mass estimated from calibration of the size-exclusion column (ca. 43 kDa), suggesting a 1:1:1 binding stoichiometry.
N-terminal sequencing of P-EPTX-Aa1a subunits
Partial N-terminal sequences of the 〈-, ®-, and ©-subunits were determined by Edman degradation. The α-and β-subunits showed a high degree of homology to each other but the γ-subunit possessed a seven residue extension at the N-terminus (Fig. 6A ). All three subunits were then subjected to a Blastp analysis of the UniProt Knowledgebase and found to show significant homology to a range of SPAN
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neurotoxin subunits (Fig. 6B ). Comparing the three subunit sequences with corresponding N-terminal fragments of other snake proteins, the subunits of P-EPTXAa1a displayed the highest overall homology to the heterotrimeric SPAN taipoxin from the coastal taipan Oxyuranus s. scutellatus [41] , with the 〈-, ®-and ©-chains of taipoxin showed 85%, 87% and 90% homology to the corresponding subunits of P-EPTX-Aa1a. Individual subunits of P-EPTX-Aa1a also showed lesser homology to subunits of the heteromultimeric SPANs cannitoxin from Oxyuranus s. canni [35] and textilotoxin from Pseudonaja textilis [42] .
Neurotoxicity studies with P-EPTX-Aa1a subunits
Of the three subunits isolated from P-EPTX-Aa1a, only the 〈-subunit (740 nM)
produced inhibition of nerve-evoked twitch contractions compared with the timematched control, resulting in 79 ± 10% neuromuscular blockade after 270 min (n = 4; produced the most rapid inhibition of twitches (t 90 = 114 ± 7 min, n = 4; Fig. 7B ), which was slower in comparison to the whole P-EPTX-Aa1a complex (one-way ANOVA, p < 0.05) but significantly more rapid than with the 〈-subunit alone. Finally, no individual P-EPTX-Aa1a subunit or recombined subunits inhibited agonist responses (Fig. 7C ).
Secretory phospholipase A 2 (sPLA 2 ) activity
The sPLA 2 activity of whole A. antarcticus venom and P-EPTX-Aa1a was determined to be 257 ± 14 µmol/min/mg and 400 ± 52 µmol/min/mg, respectively (n = 4; Fig 8A) . In comparison, the sPLA 2 activity of the positive control, Apis mellifera bee venom, was 287 ± 10 µmol/min/mg (n = 18). The 〈-subunit also displayed appreciable PLA 2 activity of 211 ± 17 µmol/min/mg (n = 6) while the ®-and ©-subunits did not exhibit any significant PLA 2 activity (n = 3).
Chemical modification of histidine residues of P-EPTX-Aa1a using 4-bromophenacyl bromide
Modification of histidines residues in P-EPTX-Aa1a using 4BPB reduced the PLA 2 activity to 20 µmol/min/mg, equivalent to ca. 5% of the original P-EPTX-Aa1a complex (Fig. 8A) . This is most likely the result of alkylation of a His 48 residue previously identified at the active site of snake PLA 2 toxins [43] . Alkylated P-EPTXAa1a caused significantly reduced toxicity in the CBCNM preparation, with only a 13 ± 3.2% reduction in twitch responses at 240 min (n = 4; Fig. 8B ). This occurred in the absence of any reduction in responses to exogenous agonists (data not shown). The vehicle (4BPB) had no effect on twitch tension or agonist responses (Fig. 8B ).
Discussion
While the venom of A. antarcticus displays classical postjunctional neurotoxicity, and is known to contain a number of long-and short-chain postsynaptic 〈-neurotoxins [17] , the present study clearly identifies the presence of a heterotrimeric SPAN complex. To our knowledge, P-EPTX-Aa1a represents the first SPAN complex to be biochemically and pharmacologically characterised from the venom of A. antarcticus. P-EPTX-Aa1a also produced a pronounced triphasic action, particularly under conditions of low quantal content, characterised by an initial brief depression, followed by a period of increased tension, and then a gradual decline to complete neuromuscular blockade. This is typical of SPANs including β-bungarotoxin [45] , taipoxin [46] , notexin [47] and crotoxin [48] , especially under conditions of high [Mg 2+ ] o [25, 26] .
P-EPTX-
Under non-denaturing conditions the molecular mass of the P-EPTX-Aa1a complex was determined as ca. 43 kDa following separation of the SPAN on a sizeexclusion column. Subsequent RP-HPLC of P-EPTX-Aa1a produced three major subunits whose combined masses, 44,698 Da, was in close agreement with the molecular mass of the SPAN complex estimated from size-exclusion chromatography. Masses and N-terminal sequences of all three P-EPTX-Aa1a subunits were similar to those found in the heterotrimeric SPAN complexes taipoxin, cannitoxin and to a lesser extent textilotoxin [35, 42] . MALDI-TOF mass spectrometry revealed the ©-subunit of P-EPTX-Aa1a to be a glycoprotein as evidenced by the areas of heterogenous glycosylation observed in the MALDI spectra. Glycosylation was also described for ©-subunits of previously isolated heterotrimeric SPAN complexes such as taipoxin [41] , cannitoxin [35] , and paradoxin [49] .
Similar to other heterotrimeric SPAN complexes, only the α-subunit of P-EPTXAa1a presented any significant PLA 2 or neurotoxic activity, likely contributing significantly to the overall toxicity of the complex. Unfortunately it is difficult to compare PLA 2 activity between studies as assay conditions vary considerably.
However, using the same colourimetric assay, cannitoxin was found to possess a similar pattern of high PLA 2 activity in the whole complex and α-subunit, albeit at a lower activity than P-EPTX-Aa1a [35] . Furthermore the lack of PLA 2 activity with the β-and γ-subunits of P-EPTX-Aa1a was mirrored in the cannitoxin study. Despite lacking any significant neurotoxic or enzyme activity all three subunits of P-EPTXAa1a appear to be necessary for maximum neurotoxicity, with equimolar recombination of all subunits yielding close to the same neurotoxicity as the native P-EPTX-Aa1a complex. This duplication of homologous subunits possibly reflects an evolutionary approach to increase the affinity of the SPAN complex for its prejunctional target and hence its neurotoxicity [50] . This is perhaps because the affinity of the complex for the nerve terminal is the product of the affinities of its individual subunits [51] , the additional subunits contribute to a better positioning of the PLA2 enzyme with respect to its substrate, and/or that they reduce non-specific binding of the active α-subunit. Regardless, the PLA 2 activity of the additional subunits is no longer important and therefore has been lost. As evidence, oligomeric SPANs such as the heterotrimeric taipoxin and paradoxin and heterohexameric textilotoxin are more potent than monomeric SPANs such as notexin, notechis II-5
and pseudexin-A in lethality studies (see [17] ).
When 4BPB was used to chemically modify the active site of P-EPTX-Aa1a, both the enzymatic and neurotoxic activity were significantly inhibited, suggesting His 48 at the catalytic site is important for neurotoxic activity at the neuromuscular junction.
This loss of neurotoxicity following alkylation with 4BPB has been previously noted with other SPANs [35, 52, 53] , although it may result from conformational changes in the toxin and an altered ability to form high affinity interactions with its specific binding protein target [54] . Nevertheless, recent studies using a single H48Q point mutation at the active site of the neurotoxic SPAN OS 2 , unlikely to cause any structural perturbations at the interfacial surface, completely inhibited activity in the CBCNM preparation but only reduced lethality by icv injection by 16-fold [55] . This finding supports the idea that sPLA 2 activity is important for neurotoxicity at the neuromuscular junction but not for central neurotoxicity.
Further support that P-EPTX-Aa1a is a SPAN complex was provided by the ability of P-EPTX-Aa1a to induce fade in tetanic tension as has been previously reported for a number of SPAN complexes [36] , but not postsynaptic snake 〈-neurotoxins [56] , during the development of neuromuscular blockade. This is hypothesised to result from a block of prejunctional α3β2 cholinergic receptors that normally mediate autofacilitation of ACh release during high frequency stimulation at the neuromuscular junction [57] . Conversely, tetanic fade may also result from a block of prejunctional adenosine A 2 receptors previously shown to enhance neurotransmitter release [58] . Interestingly, agents that block A 2 -mediated enhancement of ACh release have a very slow timecourse of action which may go some way to explain the enhanced degree of tetanic fade at lower concentrations of P-EPTX-Aa1a, presumably resulting from a slower timecourse of neuromuscular blockade. Of course tetanic fade may be the consequence of the external or internal mechanisms to interfere with synaptic vesicle release and recycling seen with SPANs (for a review see [59] ). Regardless of the mechanism(s) that produces tetanic fade, it is a clinically important phenomenon that no doubt contributes to muscle fatigue in envenomed patients, particularly if the safety factor for neurotransmission has been compromised due to slowly developing neuromuscular blockade.
We investigated the efficacy of the polysulfonated naphthylurea antitrypanosomal drug suramin to reverse neuromuscular blockade as it has been previously shown to inhibit the myotoxic and neurotoxic effect of bothropstoxin-I [37] .
Being a strongly acidic polysulfonated substance, it may neutralise the sPLA 2 neurotoxic activity by forming acid-base complexes, as seen with other polyanionic compounds such as heparin [60] . Suramin has been proven effective in prolonging time to paralysis with the presynaptic neurotoxins ®-bungarotoxin and crotoxin [38] .
Preincubation with both monovalent death adder antivenom and suramin were effective in the prevention or significant delay of neurotoxicity, respectively. However, reversal of neurotoxicity with antivenom and suramin had varying degrees of effectiveness. Considering the partial effectiveness of suramin in slowing the onset of toxicity, this may be a complimentary treatment to antivenom to prevent delayed onset toxicity in death adder envenomation. Importantly, however, suramin has shown no effectiveness against postsynaptic α-neurotoxins such as 〈-bungarotoxin [38] , and is likely to have little effect against the postsynaptic 〈-neurotoxins previously identified in A. antarcticus venom (see [17] for a review).
In summary, P-EPTX-Aa1a from A. antarcticus (NSW) venom shares similar overall complex and subunit mass, degree of glycosylation, neurotoxicity, pattern of sPLA 2 activity and sequence homology to the subunits of other high molecular mass heterotrimeric SPAN complexes. In particular, P-EPTX-Aa1a displays the highest overall homology with taipoxin and cannitoxin, from the coastal and Papuan taipan, respectively, belonging to same Acanthophiinae subfamily as Acanthophis spp.
Importantly, while early preincubation of antivenom prevented the onset of neurotoxicity, late administration of antivenom (at t 90 ) failed to neutralize the in vitro neurotoxicity of P-EPTX-Aa1a. Therefore, since A. antarcticus (NSW) venom contains a potent irreversible SPAN, clinicians may need to be attentive of possible presynaptic neurotoxicity following envenomation by this snake and most likely many other Acanthophis spp. [21] . Therefore early intervention with antivenom is critically important in preventing severe prolonged envenomation from A. antarcticus and other Australo-Papuan death adders. Determination of the molecular mass of P-EPTX-Aa1a. Log molecular weight versus retention ration (V e / V o ) standard curve for the calibration of the Superdex G-75 column using a series of molecular weight standards. The molecular mass of P-EPTX-Aa1a was determined to be ca. 43 kDa. 
